Cargando…
Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer often diagnosed late. Earlier detection is urgently needed. Pancreatic ductal adenocarcinoma is known to associate with increased coagulation activity. We studied whether preoperative coagulation biomarkers are useful in distinguishing PDAC...
Autores principales: | Mattila, Nora, Seppänen, Hanna, Mustonen, Harri, Przybyla, Beata, Haglund, Caj, Lassila, Riitta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714782/ https://www.ncbi.nlm.nih.gov/pubmed/29865859 http://dx.doi.org/10.1177/1076029618779133 |
Ejemplares similares
-
Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer
por: Eurola, Annika, et al.
Publicado: (2022) -
Matrix Metalloproteinase 8 Expression in a Tumour Predicts a Favourable Prognosis in Pancreatic Ductal Adenocarcinoma
por: Kaasinen, Mirjami, et al.
Publicado: (2022) -
Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
por: Nurmi, Anna M., et al.
Publicado: (2021) -
Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Salmiheimo, Aino, et al.
Publicado: (2016) -
Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2015)